These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 36111393

  • 1. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
    Conde-Estévez D, Henríquez I, Muñoz-Rodríguez J, Rodriguez-Vida A.
    Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Zhang X, Zhang G, Wang J, Bi J.
    Front Endocrinol (Lausanne); 2023 Sep; 14():1131033. PubMed ID: 36843606
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND.
    JAMA Netw Open; 2024 Aug 01; 7(8):e2429783. PubMed ID: 39190308
    [Abstract] [Full Text] [Related]

  • 9. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
    Appukkuttan S, Ko G, Fu C, Bannister B, Kong SX, Jhaveri J, Freedland SJ.
    Expert Rev Anticancer Ther; 2024 May 01; 24(5):325-333. PubMed ID: 38469875
    [Abstract] [Full Text] [Related]

  • 10. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
    Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR.
    Future Oncol; 2023 Feb 01; 19(5):385-395. PubMed ID: 36794575
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X, Wang Q, Pan Y, Wang S, Li Y, Zhang H, Xu M, Zhou H, Liu X.
    Front Endocrinol (Lausanne); 2023 Feb 01; 14():1134719. PubMed ID: 36967752
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice.
    Bögemann M, Facchini G, Bauernhofer T, Cathomas R, Xylinas E, Tombal B.
    Ir J Med Sci; 2023 Dec 01; 192(6):2643-2651. PubMed ID: 36944842
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A, Jiang S, Varghese D, Appukkuttan S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Corman S.
    BMC Cancer; 2022 Mar 22; 22(1):304. PubMed ID: 35317768
    [Abstract] [Full Text] [Related]

  • 19. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Schultz NM, O'Day K, Sugarman R, Ramaswamy K.
    J Manag Care Spec Pharm; 2020 Apr 22; 26(4):538-549. PubMed ID: 32020841
    [Abstract] [Full Text] [Related]

  • 20. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
    Moussa M, Lazarou L, Dellis A, Abou Chakra M, Papatsoris A.
    Expert Opin Pharmacother; 2021 Mar 22; 22(4):397-402. PubMed ID: 33135506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.